Journal Article Summary
The article investigates the effectiveness of a combination therapy using 0.1% fluorometholone and 0.05% azelastine for treating severe allergic conjunctival diseases (ACD). This topic is significant because ACD affects a large portion of the population and can severely impact eye health and quality of life. Severe forms of ACD, such as vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC), can lead to serious complications if not treated effectively, making it crucial to find optimal treatment strategies.
In this randomized controlled trial, 111 patients with severe ACD were divided into two groups: one received fluorometholone alone, while the other received the combination of fluorometholone and azelastine. The researchers measured various symptoms and signs of the disease, including the Ocular Surface Disease Index (OSDI) and signs of keratopathy, at multiple time points during the six-week treatment period. Results showed that while both treatments improved symptoms, the combination therapy led to significantly better outcomes across all measured parameters, indicating that azelastine enhances the effectiveness of fluorometholone.
Despite the promising findings, the study has limitations. Notably, visual acuity was not assessed, which is important for evaluating treatment safety. Additionally, the six-week treatment duration may not be sufficient for some severe cases, and the potential side effects of prolonged steroid use, such as elevated intraocular pressure (IOP), need careful monitoring. Patients should discuss these findings with their healthcare providers, especially regarding the risks and benefits of using these medications, and ensure regular follow-ups to monitor for any adverse effects.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Chen Minjie, Ke Bilian, Zou Jun, Gong Lan, Wang Yan, Zhang Chaoran, Xu Jianjiang, Wei Anji, et al.. Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial. Journal of Clinical Medicine 2022. DOI: 10.3390/jcm11133877. PMID: 35807160. PMCID: PMC9267215.
Featured Pill Pals Product
Azelastine Nasal Solution One Percent (1%) 30 ml --- Generic For Astelin --- 137 mcg --- 200 Metered Sprays --- Apotex Pharma
Azelastine Nasal Solution One Percent (1%) 30 ml — Generic For Astelin — 137 mcg — 200 Metered Sprays — Apotex Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
